Enanta Pharmaceuticals Inc (ENTA) income statement
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.23−0.46 (-5.29%)
Close on Nov 18, 2026Market cap $239.70MP/E –Yield –
Enanta Pharmaceuticals Inc income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -99.0%
- Net margin
- -108.3%
- Return on equity, FY2026
- -94.2%
Financial strength
- Current ratio
- 3.78
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 37.2%
Valuation
- P/E ratio
- –
- Price to sales
- 3.80
- Price to book
- 2.99
- Dividend yield
- –
See a number that looks wrong?